Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease

Author(s): Stergios A. Polyzos*, Gema Frühbeck and Dimitrios N. Kiortsis

Volume 29, Issue 41, 2023

Published on: 18 December, 2023

Page: [3263 - 3265] Pages: 3

DOI: 10.2174/0113816128279822231211101522

Price: $65

Next »
[1]
Athyros VG, Polyzos SA, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; New kids on the block. Curr Vasc Pharmacol 2020; 18(2): 172-81.
[http://dx.doi.org/10.2174/1570161117666190405164313] [PMID: 30961499]
[2]
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73(1): 202-9.
[http://dx.doi.org/10.1016/j.jhep.2020.03.039] [PMID: 32278004]
[3]
Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 101133.
[http://dx.doi.org/10.1016/j.jhep.2023.06.003] [PMID: 37364790]
[4]
Polyzos SA, Kang ES, Tsochatzis EA, et al. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism 2020; 113: 154413.
[http://dx.doi.org/10.1016/j.metabol.2020.154413] [PMID: 33164861]
[5]
Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111: 154203.
[http://dx.doi.org/10.1016/j.metabol.2020.154203] [PMID: 32151660]
[6]
Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med 2022; 12(7): 1166.
[http://dx.doi.org/10.3390/jpm12071166] [PMID: 35887662]
[7]
Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports 2021; 3(5): 100322.
[http://dx.doi.org/10.1016/j.jhepr.2021.100322] [PMID: 34693236]
[8]
Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity medications for the management of nonalcoholic fatty liver disease. Curr Obes Rep 2022; 11(3): 166-79.
[http://dx.doi.org/10.1007/s13679-022-00474-0] [PMID: 35501557]
[9]
Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387(10019): 679-90.
[http://dx.doi.org/10.1016/S0140-6736(15)00803-X] [PMID: 26608256]
[10]
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384(12): 1113-24.
[http://dx.doi.org/10.1056/NEJMoa2028395] [PMID: 33185364]
[11]
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385(6): 503-15.
[http://dx.doi.org/10.1056/NEJMoa2107519] [PMID: 34170647]
[12]
Polyzos SA, Goulas A, Papaioannidou P. Tirzepatide for diabetes and obesity: A new window to the treatment of non-alcoholic steatohepatitis. Curr Med Chem 2023; 30(22): 2476-9.
[http://dx.doi.org/10.2174/0929867330666230106103202] [PMID: 36617715]
[13]
Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 2020; 43(6): 1352-5.
[http://dx.doi.org/10.2337/dc19-1892] [PMID: 32291277]
[14]
Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022; 10(6): 393-406.
[http://dx.doi.org/10.1016/S2213-8587(22)00070-5] [PMID: 35468325]
[15]
Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol 2023; 79(4): 888-97.
[http://dx.doi.org/10.1016/j.jhep.2023.05.013] [PMID: 37355043]
[16]
Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study. Diabetes Care 2021; 44(6): 1433-42.
[http://dx.doi.org/10.2337/dc20-2151] [PMID: 34016612]
[17]
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity-A phase 2 trial. N Engl J Med 2023; 389(6): 514-26.
[http://dx.doi.org/10.1056/NEJMoa2301972] [PMID: 37366315]
[18]
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402(10401): 529-44.
[http://dx.doi.org/10.1016/S0140-6736(23)01053-X] [PMID: 37385280]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy